ClinicalTrials.Veeva

Menu

Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score

P

Poitiers University Hospital

Status and phase

Completed
Phase 2

Conditions

Feeling Anxious

Treatments

Drug: Pregabalin
Drug: hydroxyzine
Drug: Lactose

Study type

Interventional

Funder types

Other

Identifiers

NCT01675986
GABAPAC

Details and patient eligibility

About

The insertion of long-lasting intravenous device is done under local anesthesia. Currently, in the investigators hospital, no premedication is given to the patients. However, this procedure occurs in a particular emotional context related to the diagnosis of cancer or malign hemopathies.

Therefore, administration of a sedative or anxiolytic drugs before the start of the procedure can be questionable.

Hydroxyzine is the reference molecule for premedication because of its anxiolytic and anti-histaminic properties A new agent, pregabalin, shares also the same properties

The main objective of this study was to compare the efficacy of pregabalin and hydroxyzine on the anxiety score as a premedication during the insertion of long-lasting intravenous device under local anesthesia.

Enrollment

306 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged from 18 to 75 years
  • Patient schedules for insertion of long-lasting intravenous device

Exclusion criteria

  • History of previous insertion of long-lasting intravenous device or central intravenous catheter
  • long term treatment of gabapentin or pregabalin
  • Hypersensitivity to pregabalin or any of the excipients
  • Hypersensitivity to hydroxyzine, one of its metabolites, one of the excipients, another derivative of piperazine, aminophylline or ethylene diamine.
  • Patient at risk of glaucoma e
  • Patient at risk for urinary retention
  • Patient severe respiratory failure
  • Patient at the general condition not too corrupted (ASA IV)
  • Renal failure with creatinin clearance < 30 ml / min
  • Patient not affiliated to Social Security
  • Pregnant or lactating
  • Patients in emergency situations
  • Inpatient without consent

Trial design

306 participants in 3 patient groups, including a placebo group

Pregabaline
Experimental group
Description:
Groups PREGABALINE : 150 mg de LYRICA®
Treatment:
Drug: Pregabalin
Hydroxyzine
Experimental group
Description:
Groups HYDROXYZINE : 75 mg d'ATARAX®
Treatment:
Drug: hydroxyzine
Lactose
Placebo Comparator group
Description:
Groups placebo : 4 g de lactose
Treatment:
Drug: Lactose

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems